Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease
Parkinson's Disease
About this trial
This is an interventional treatment trial for Parkinson's Disease focused on measuring Parkinson's Disease, Foslevodopa/foscarbidopa, ABBV-951, Levodopa (LD), Carbidopa (CD)
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of idiopathic Parkinson's disease (PD) that is Levodopa-responsive.
- Must be taking a minimum of 400 mg/day of levodopa equivalents (LE) and be judged by the investigator to have motor symptoms inadequately controlled by current therapy.
- Must have recognizable/identifiable "Off" and "On" states (motor fluctuations), and have a minimum daily average of 2.5 hours of "Off" time (with a minimum of 2 hours of "Off" time each day).
Exclusion Criteria:
- History of significant skin conditions or disorders (e.g., psoriasis, atopic dermatitis, etc.) or evidence of recent sunburn, acne, scar tissue, tattoo, open wound, branding, or colorations that in the investigator's opinion would interfere with the infusion of the study drug or could interfere with study assessments.
Sites / Locations
- University of Colorado Hospital /ID# 229974
- Georgetown University Hospital /ID# 230224
- Rush University Medical Center /ID# 229983
- Carolina Phase 1, LLC /ID# 239836
- The Movement Disorder Clinic of Oklahoma /ID# 238610
- Vanderbilt University Medical Center /ID# 230255
- Parkinson Disease Movement Disorders Clinic /ID# 245791
- Texas Movement Disorder Specialists /ID# 238607
- Baylor College of Medicine - Baylor Medical Center /ID# 239631
- University of Utah Health Care /ID# 241219
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Arm 1: ABBV-951
Arm 2: ABBV-951
Arm 3: ABBV-951
Arm 4: ABBV-951
Participants will receive ABBV-951 for 2 consecutive days in the abdomen (Period 1), flank (Period 2), arm (Period 3) and thigh (Period 4).
Participants will receive ABBV-951 for 2 consecutive days in the arm (Period 1), abdomen (Period 2), thigh (Period 3) and flank (Period 4).
Participants will receive ABBV-951 for 2 consecutive days in the thigh (Period 1), arm (Period 2), flank (Period 3) and abdomen (Period 4).
Participants will receive ABBV-951 for 2 consecutive days in the flank (Period 1), thigh (Period 2), abdomen (Period 3) and arm (Period 4).